Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress

We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Legend Biotech Corporation (NASDAQ:LEGN) is among the best healthcare stocks.

TheFly reported on June 3 that UBS increased its price target on LEGN to $49 from $31 while reiterating a Buy rating on the stock. The firm cited promising early clinical findings from the company’s LB5006 program, noting evidence of therapeutic activity at the higher dose level. UBS also highlighted the treatment’s favorable initial safety observations, which contributed to its positive outlook on the program’s development potential.

Moreover, on June 14, Legend Biotech Corporation (NASDAQ:LEGN) reported initial clinical proof-of-concept results for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy for relapsed or refractory B-cell non-Hodgkin lymphoma. Data from an ongoing Phase 1 study showed that a single infusion produced dose-related CAR-T cell expansion without requiring lymphodepletion. At the higher dose level, the therapy delivered a 100% objective response rate and an 83.3% complete response rate, with all responses remaining active at the data cutoff date.

Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress

LB2501 also demonstrated a favorable tolerability profile, with no dose-limiting toxicities, serious adverse events, neurotoxicity events, or treatment-related deaths reported. The findings support the potential of the company’s in vivo CAR-T platform and further advancement of the program.

Legend Biotech Corporation (NASDAQ:LEGN) is a commercial-stage biopharmaceutical company developing and manufacturing innovative cell therapies, with a strong focus on CAR-T treatments for cancer.

While we acknowledge the risk and potential of LEGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LEGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1